How AZ’s respiratory wins are ramping up for a bigger prize in COPD

In Dr. Donna Carstens’ career as a pulmonologist, now senior medical director for the biologic respiratory drug Fasenra at AstraZeneca, she’s seen the field take a full-on paradigm shift from “treat-to-fail” to “treat-to-target.”